|
rs20417
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The aim of this study was to investigate the association between the cyclooxygenase 2 (COX2) -765G>C (rs20417) polymorphism and prostate cancer (PC) risk using meta-analysis.
|
26535654 |
2015 |
|
rs20417
|
|
|
0.040 |
GeneticVariation |
BEFREE |
When all groups were pooled, we did not detect a significant association of rs20417 polymorphism with prostate cancer risk.
|
22782583 |
2012 |
|
rs20417
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In a hospital-based case/control study, 195 subjects with PCa and 250 healthy controls were investigated for the association of COX-2 -765 G>C (rs20417) and +8473 T>C (rs5275) promoter polymorphism with PCa susceptibility using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method.
|
22023987 |
2011 |
|
rs20417
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We found no evidence that rs20417</span> alters prostate cancer</span> risk (odds</span> ratio (OR(CC & GC v GG)=1.05, 95% confidence interval (CI)=0.91-1.20).
|
19488068 |
2009 |
|
rs2745557
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Also, the coexistence of COX-2 (rs2745557) and obesity, smoking, or diabetes may lead to the development of PCa or BPH.
|
26920155 |
2016 |
|
rs2745557
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Based on our meta-analysis, COX-2 rs2745557 was associated with a lower PCa risk under dominant model in Caucasians.
|
22435969 |
2012 |
|
rs2745557
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Three SNPs demonstrated nominally statistically significant associations with prostate cancer risk, with the most compelling polymorphism (rs2745557) associated with a lower risk of disease (odds ratio (OR) GC vs GG=0.64; 95% confidence interval (CI): 0.49-0.84; P=0.002).
|
17609663 |
2007 |
|
rs5275
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In a hospital-based case/control study, 195 subjects with PCa and 250 healthy controls were investigated for the association of COX-2 -765 G>C (rs20417) and +8473 T>C (rs5275) promoter polymorphism with PCa susceptibility using the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method.
|
22023987 |
2011 |
|
rs5275
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In PLCO, the Ex10 +837 T>C marker (rs5275) was initially associated with prostate cancer risk (P-trend = 0.02) but became non-significant after adjustment for multiple comparisons (P = 0.08); this SNP showed no association with prostate cancer risk in the Nutrition Cohort (P-trend = 0.54) or in an analysis pooling the two cohorts (P-trend = 0.20).
|
17999989 |
2008 |
|
rs689465
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results support the hypothesis that rs689465 influences susceptibility to prostate cancer; however, prostate cancer progression was not associated with rs689465 in a Japanese population.
|
24203817 |
2014 |
|
rs748500299
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study demonstrated a relationship between the COX2 G1195A variant and prostate cancer risk.
|
24203817 |
2014 |
|
rs689470
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, we found that rs689470</span> was significantly associated with a trend towards increased prosta</span>te cancer risk when using both additive (OR = 2.15, 95%CI = 1.04-4.44, P = 0.04) and recessive models (OR = 2.07, 95%CI = 1.07-4.03, P = 0.03) to analyze the data.
|
22782583 |
2012 |
|
rs689466
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjustment for confounders, polymorphisms in COX-2 (rs689466) and IL-8 (rs4073) were not significantly associated with prostate cancer risk.
|
20431935 |
2010 |